Involvement of RB kinases and phosphatases in life and death decisions

Previously we found that retinoblastoma protein (RB) became dephosphorylated in an early stage of DNA damage-induced, p53-independent apoptosis. Here, we report that both RB dephosphorylation and apoptosis are regulated by relative levels of RB kinases (cyclin-dependent kinases, or cdks) and phosphatases. Treatment of human Jurkat T cells with roscovitine, a potent and selective synthetic inhibitor of several cdks, rapidly induced RB dephosphorylation, which was followed by induction of apoptosis-associated internucleosomal DNA fragmentation. The roscovitine treatment did not increase levels of the endogenous cdk inhibitor proteins p16(Ink4a), p27(kip1) and p21(Waf1), supporting the idea that the observed RB dephosphorylation was due to a direct inhibition of cdk activities by roscovitine. Treatment with a protein kinase C inhibitor (sphingosine or staurosporine), which leads to suppression of several cdk kinase activities, also induced cellular RB dephosphorylation and apoptosis. Finally, roscovitine- or sphingosine-induced RB dephosphorylation was blocked by a specific inhibitor of protein-serine/threonine phosphatases (calyculin A or okadaic acid). Therefore, RB phosphorylation status and cellular fate are regulated by the ratio of RB kinases to RB phosphatases.

Society for Neuroscience--30th Annual Meeting. Alzheimer's disease: Therapeutics, targets and screens

In the early 1990s, genetic mapping of the amyloid precursor protein (APP) locus and the markers linking it to FAD were recent discoveries. Since then, Alzheimer's disease (AD) research has progressed from the identification of FAD-linked mutation to the generation of transgenic animals that express these mutant genes. Transgenic animals can represent models of aberrant beta-amyloid (Abeta) production either through the expression of mutant APP genes or mutant presenilin (PS)-1 genes, or both. Currently, this plethora of well-characterized animal models is being applied to test candidate therapeutic agents and strategies to reverse or prevent amyloid deposition into plaques. Treatments included specific inhibitors of the enzymes that produce Abeta, non-steroidal anti-inflammatory therapies (NSAIDs), Abeta-chelating agents and dietary supplements.

Alzheimer's disease and stroke

This report focuses on the two most common neurological diseases in man: Alzheimer's disease (AD) and stroke. One common feature of both of these diseases is the death of cells, particularly neurons. Since a typical mechanism of cell death is apoptosis, this will be an additional focal point in this report.

The growth inhibitor of African green monkey (BSC-1) cells is transforming growth factors beta 1 and beta 2

The growth inhibitory activity in conditioned medium of African green monkey kidney epithelial (BSC-1) cells that has been shown to arise, at least in part, from transforming growth factor beta 2 (TGF-beta 2) [Hanks, S. K., Armour, R., Baldwin, J. H., Maldonado, F., Spiess, J., & Holley, R. W. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 79-82] was tested for growth inhibitory activity prior to and following acidification. Similar to TGF-beta 1 from human platelets, the inhibitory activity from BSC-1 cells demonstrated an 8-10-fold stimulation following acidification, showing that the activity was secreted from the cells in latent form. Conditioned medium from BSC-1 cells was collected, acidified, and fractionated by procedures that separate TGF-beta 1 and -2. Biological activity was assayed by using the BSC-1 cell proliferation assay. Two active proteins with properties similar to known TGF-beta 1 and TGF-beta 2 were identified. Identity was confirmed by using immunological and amino acid sequencing techniques. These results were consistent with Northern blot analysis of total BSC-1 RNA, using cDNA probes for TGF-beta 1 and TGF-beta 2, which demonstrated strong signals for both mRNAs. Metabolic labeling in conjunction with two-dimensional gel electrophoresis revealed that the cells secrete approximately 10% TGF-beta 1 and 90% TGF-beta 2.